Human Plasma Cells Engineered to Produce Bi-Specific T Cell Engagers Show In Vivo Anti-Tumor Efficacy

被引：0
|
作者：
Hill, Tyler [1 ]
Narvekar, Parnal [1 ]
Asher, Gregory [1 ]
Camp, Nathan [1 ]
Thomas, Kerri [1 ]
Tasian, Sarah [2 ,3 ]
Rawlings, David J. [4 ,5 ,6 ]
James, Richard [4 ,5 ,7 ]
机构：
[1] Seattle Childrens Res Inst Seattle, Seattle, WA USA
[2] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA USA
[3] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA USA
[4] Seattle Childrens Res Inst, Seattle, WA USA
[5] Univ Washington, Dept Pediat, Seattle, WA USA
[6] Univ Washington, Dept Immunol, Seattle, WA USA
[7] Univ Washington, Dept Pharmacol, Seattle, WA USA
来源：
MOLECULAR THERAPY | 2023年 / 31卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
575
引用
收藏
页码：290 / 290
页数：1
相关论文
共 50 条
  • [21] Potent soluble linear T cell engagers for the ex vivo expansion of human T cells
    Gariepy, Jean
    Matus, Esther
    Sparkes, Amanda
    JOURNAL OF IMMUNOLOGY, 2024, 212 (01):
  • [22] IMMUNOTHERAPEUTIC ANTI-TUMOR EFFECT OF ENGINEERED T CELLS IN A PATIENT-SPECIFIC COLORECTAL CANCER-ON-A-CHIP
    Min, Soyoun
    Shin, Yong Cheol
    Wu, Alexander
    Than, Nam
    Kim, Hyun Jung
    GASTROENTEROLOGY, 2023, 164 (06) : S1000 - S1000
  • [23] T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy
    Raber, Patrick
    Sierra, Rosa A.
    Zhang, Shuzhong
    Thevenot, Paul
    Rodriguez, Paulo C.
    CANCER RESEARCH, 2016, 76
  • [24] T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy
    Raber, Patrick L.
    Sierra, Rosa A.
    Thevenot, Paul T.
    Zhang Shuzhong
    Wyczechowska, Dorota D.
    Kumai, Takumi
    Celis, Esteban
    Rodriguez, Paulo C.
    ONCOTARGET, 2016, 7 (14) : 17565 - 17578
  • [25] Engineered red-cell therapeutics (RCT) as artificial antigen presenting cells promotein vivoexpansion and anti-tumor activity of antigen specific T cells
    Zhang, Xuqing
    Dastagir, Shamael R.
    Subbiah, Naren
    Luo, Mengyao
    Soman, Vikram
    Pawar, Sneha
    McLaughlin, Douglas C.
    Bayhi, Nicholas
    Amin, Viral
    Nissen, Torben Straight
    Carpenter, Christopher L.
    Wickham, Thomas J.
    Chen, Tiffany F.
    CANCER RESEARCH, 2019, 79 (13)
  • [26] In vivo anti-tumor activity of genetically modified T cells is dependent on the method of ex vivo T cell expansion.
    Brentjens, RJ
    Latouche, JB
    Riviere, I
    Sadelain, M
    BLOOD, 2002, 100 (11) : 577A - 577A
  • [27] Human melanoma therapy in the SCID mouse:: In vivo targeting and reactivation of melanoma-specific cytotoxic T cells by bi-specific antibody fragments
    Cochlovius, B
    Perschl, A
    Adema, GJ
    Zöller, M
    INTERNATIONAL JOURNAL OF CANCER, 1999, 81 (03) : 486 - 493
  • [28] Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases ( vol 15, 1335998, 2024)
    Perico, Luca
    Casiraghi, Federica
    Sonego, Fabiane
    Todeschini, Marta
    Corna, Daniela
    Cerullo, Domenico
    Pezzotta, Anna
    Isnard-Petit, Patricia
    Forneris, Federico
    Faravelli, Silvia
    Thiam, Kader
    Benigni, Ariela
    Remuzzi, Giuseppe
    FRONTIERS IN IMMUNOLOGY, 2025, 15
  • [29] Non-Virally Engineered Polyclonal.d T Cells Exhibit Potent Anti-Tumor Activity In Vivo
    Bridge, Jacob
    Claudio-Vazquez, Patricia
    Wenthe, Sophia
    Krueger, Joshua
    Moriarity, Branden S.
    Webber, Beau
    MOLECULAR THERAPY, 2023, 31 (04) : 144 - 145
  • [30] Enhancing the Efficacy of Anti-tumor Immunotherapy by Targeting T cell Metabolism
    Xin Pei Ji
    Qiu Yan Liu
    JournalofNutritionalOncology, 2019, 4 (02) : 67 - 73
12345